KLK3 and Familial prostate cancer: The findings of this large, randomized clinical trial indicate that a biomarker-based risk prediction approach combining the Stockholm3 risk score with systematic biopsies is comparable with an MRI-enhanced strategy involving PSA levels and both systematic and targeted biopsies for detecting clinically significant prostate cancers as part of a screening program.